monosaccharide/seizures

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

15 rezilta yo

Use of topiramate in childhood generalized seizure disorders.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Topiramate is a sulfamate derivative of the naturally occurring monosaccharide D-fructose. It was initially approved in the United States as adjunctive therapy for partial seizures in 1997. However, there is increasing evidence that it is effective in the treatment of generalized seizures and

Topiramate-induced angle closure with acute myopia, macular striae.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Topiramate is a sulfamate-substituted monosaccharide used in the treatment of seizures, and prophylaxis of migraine. A number of ocular side-effects have been described with use of topiramate, like bilateral angle closure, acute myopia and macular striae. Ultrasound biomicroscopy (UBM) clinches the

Urolithiasis associated with topiramate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Topiramate is a sulfamate-substituted monosaccharide anticonvulsant used as adjunctive therapy for intractable refractory seizures. It is report a case of topiramate-induced urolithiasis. METHODS A 35-year-old man presented with acute, right-sided, colicky flank pain. He denied hematuria

Topiramate efficacy in infancy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Topiramate is a sulfamate-substituted monosaccharide that has demonstrated efficacy as an antiepileptic drug in adults with partial onset seizures. Experience in children has been limited, but early reports have supported its safety and effectiveness in children as young as 2 years of age. In two

Topiramate. Clinical profile in epilepsy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Topiramate, a sulfamate-substituted monosaccharide, is a new antiepileptic drug (AED) approved as adjunctive therapy for partial-onset seizures in adults. Topiramate is rapidly absorbed, has linear pharmacokinetics, minimal protein binding and a long half-life facilitating a twice-daily dosage

Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Since 1990 eight new antiepileptic drugs (AEDs) have been developed. Among these new drugs, Topiramate (TPM) is one of the latest AEDs available for treating drug resistant partial epilepsy both in adults and in children. The mechanisms underlying TPM antiepileptic activity are still incompletely

Rapid approach to the quantitative determination of topiramate (2, 3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate) in human plasma by liquid-liquid extraction and flow-injection negative-ion electrospray mass spectrometry.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Topiramate, a sulfamate-substituted monosaccharide (2,3:4, 5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate), is a new antiepileptic drug, which has been approved for adjunctive therapy in adult patients with partial-onset seizures. Liquid-liquid extraction followed by flow-injection

Hypohidrosis related to the administration of topiramate to children.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Topiramate (TPM) is an antiepileptic agent, first licensed in the United Kingdom in 1994, that is used in the treatment of patients with refractory seizure disorders. TPM is a monosaccharide d-fructose derivate, with sulfamate function, and so far, few adverse side effects have been

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Positive caloric balance often causes pathologic adipocyte and adipose tissue anatomical and functional changes (termed adiposopathy or 'sick fat'), which may lead to pathogenic adipocyte and adipose tissue responses and metabolic disease. Fat weight loss may improve adiposopathy, and thus improve

Topiramate: a new antiepileptic drug.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage of topiramate are reviewed. Topiramate is indicated for use in the adjunctive treatment of adult partial-onset epilepsy. A sulfamate-substituted monosaccharide, it is structurally distinct from

[Current clinical evidence on topiramate pharmacokinetics].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Topiramate is biochemically classified as a fructopyranose sulphamate. Discovered as early as 1979, during middle 1980's it was approved in many countries for the treatment of epilepsies and migraine prevention. More recently, in the experimental stage, possible new indications have been disclosed:

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Phentermine hydrochloride is a noradrenergic sympathetic amine approved for decades by the U.S. Food and Drug Administration (FDA) at doses as high as 37.5 mg/day for the short-term treatment of obesity. Topiramate is a sulfamate-substituted monosaccharide marketed since 1996, and approved by the

Topiramate: a review of preclinical, pharmacokinetic, and clinical data.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The antiepileptic drug (AED) topiramate is a monosaccharide derivative with a sulfamate functionality. It modulates voltage-dependent sodium conductance, potentiates gamma-aminobutyric acid-evoked currents, and blocks the kainate/AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid)

Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Topiramate is a sulphamate-substituted monosaccharide derived from D-fructose and is structurally unrelated to other antiepileptic drugs. It acts by multiple mechanisms that suggest it may be effective in several types of epilepsy. In double-blind placebo-controlled trials, add-on therapy with

Congenital Disorders of Ganglioside Biosynthesis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Gangliosides are expressed on all vertebrate cells and tissues, but are particularly abundant in the mammalian brain, where they constitute major cell-surface determinants on all nerve cells. The same four ganglioside structures, GM1, GD1a, GD1b, and GT1b, constitute the great majority of brain

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye